IκBζ is a key driver in the development of psoriasis
- 12 October 2015
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 112 (43), E5825-E5833
- https://doi.org/10.1073/pnas.1509971112
Abstract
Psoriasis is a common immune-mediated, chronic, inflammatory skin disease characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Although TNFα- and IL-17A–targeting drugs have recently proven to be highly effective, the molecular mechanism underlying the pathogenesis of psoriasis remains poorly understood. We found that expression of the atypical IκB member IκB (inhibitor of NF-κB) ζ, a selective coactivator of particular NF-κB target genes, was strongly increased in skin of patients with psoriasis. Moreover, in human keratinocytes IκBζ was identified as a direct transcriptional activator of TNFα/IL-17A–inducible psoriasis-associated proteins. Using genetically modified mice, we found that imiquimod-induced psoriasis-like skin inflammation was completely absent in IκBζ-deficient mice, whereas skin inflammation was still inducible in IL-17A– and TNFα-deficient mice. IκBζ deficiency also conferred resistance against IL-23–induced psoriasis. In addition, local abrogation of IκBζ function by intradermal injection of IκBζ siRNA abolished psoriasis-like skin inflammation. Taken together, we identify IκBζ as a hitherto unknown key regulator of IL-17A–driven effects in psoriasis. Thus, targeting IκBζ could be a future strategy for treatment of psoriasis, and other inflammatory diseases for which IL-17 antagonists are currently tested in clinical trials.Keywords
This publication has 51 references indexed in Scilit:
- Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasisCurrent Opinion in Rheumatology, 2015
- A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2014
- IL-17 Induces Inflammation-Associated Gene Products in Blood Monocytes, and Treatment with Ixekizumab Reduces Their Expression in Psoriasis Patient BloodJournal of Investigative Dermatology, 2014
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentJournal of the American Academy of Dermatology, 2014
- The IL-23–IL-17 immune axis: from mechanisms to therapeutic testingNature Reviews Immunology, 2014
- IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanismsProceedings of the National Academy of Sciences of the United States of America, 2014
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Transcriptome Analysis of Psoriasis in a Large Case–Control Sample: RNA-Seq Provides Insights into Disease MechanismsJournal of Investigative Dermatology, 2014
- IκBζ Is a Transcriptional Key Regulator of CCL2/MCP-1Published by The American Association of Immunologists ,2013
- The complexity of NF-κB signaling in inflammation and cancerMolecular Cancer, 2013